Literature DB >> 17406986

Establishment of a novel orthotopic xenograft model of human gallbladder carcinoma.

Jan-Hendrik Egberts1, Bodo Schniewind, Clemens Schafmayer, Marie-Luise Kruse, Bence Sipos, Fred Fändrich, Holger Kalthoff, Jürgen Tepel.   

Abstract

OBJECTIVE: Gallbladder cancer is characterized by high morbidity and mortality. An appropriate human xenograft animal model could serve as a research tool to investigate new therapeutic strategies. SUMMARY BACKGROUND DATA: To date, the few reports describing a xenograft animal model showed significant limitations. We improved a murine orthotopic human xenotransplantation model by implanting human gallbladder carcinoma cells directly into the lumen of the gallbladder.
METHODS: Mz-ChA-1 cells were orthotopically injected into the gallbladder of Severe Combined Immune Deficiency (SCID) beige mice inducing the growth of solid tumors. The natural course of the disease, tumor growth, and metastases were analyzed. The cytotoxic drug gemcitabine was tested in vitro and in vitro.
RESULTS: All animals revealed solid tumors in the inoculated area with liver infiltration. The median tumor volume in the untreated group was significantly higher than in the gemcitabine-treated group. Immunohistochemical staining revealed expression of human cytokeratin 7 and cytokeratin 8. To analyze tumor cell proliferation, the tumors were stained for the antigen Ki-67, and labeling indices were calculated for both groups. Animals receiving gemcitabine treatment showed significantly lower mean labeling indices. In vitro investigation revealed a significant reduction of DNA synthesis. DNA fragmentation, as a measure of apoptosis, was elevated by roughly 20% within 24 h of treatment. With this, we successfully established an orthotopic xenotransplant animal model and investigated the in vitro and in vivo effects of gemcitabine in human xenografted Mz-ChA-1 gallbladder adenocarcinoma.
CONCLUSION: This model resembles the clinical situation as closely as possible and offers a relevant option for the preclinical testing of new therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17406986     DOI: 10.1007/s10585-007-9058-x

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  42 in total

1.  Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study.

Authors:  V Gebbia; F Giuliani; E Maiello; G Colucci; F Verderame; N Borsellino; G Mauceri; M Caruso; M L Tirrito; M Valdesi
Journal:  J Clin Oncol       Date:  2001-10-15       Impact factor: 44.544

Review 2.  The role of chemotherapy in cholangiocarcinoma.

Authors:  S Thongprasert
Journal:  Ann Oncol       Date:  2005       Impact factor: 32.976

3.  Ultrastructural and immunohistochemical analysis of cholangiocarcinoma in immunized Syrian golden hamsters infected with Opisthorchis viverrini and administered with dimethylnitrosamine.

Authors:  S Tesana; Y Takahashi; P Sithithaworn; K Ando; T Sakakura; W Yutanawiboonchai; C Pairojkul; W Ruangjirachuporn
Journal:  Parasitol Int       Date:  2000-09       Impact factor: 2.230

4.  Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial.

Authors:  Steven R Alberts; Hani Al-Khatib; Michelle R Mahoney; Lawerence Burgart; Peter J Cera; Patrick J Flynn; Tom R Finch; Ralph Levitt; Harold E Windschitl; James A Knost; Loren K Tschetter
Journal:  Cancer       Date:  2005-01-01       Impact factor: 6.860

5.  Biliary adenocarcinoma. Characterisation of three new human tumor cell lines.

Authors:  A Knuth; H Gabbert; W Dippold; O Klein; W Sachsse; D Bitter-Suermann; W Prellwitz; K H Meyer zum Büschenfelde
Journal:  J Hepatol       Date:  1985       Impact factor: 25.083

6.  Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells.

Authors:  Y Shimizu; A J Demetris; S M Gollin; P D Storto; H M Bedford; S Altarac; S Iwatsuki; R B Herberman; T L Whiteside
Journal:  Int J Cancer       Date:  1992-09-09       Impact factor: 7.396

Review 7.  Biliary proliferation and adaptation in furan-induced rat liver injury and carcinogenesis.

Authors:  A E Sirica
Journal:  Toxicol Pathol       Date:  1996 Jan-Feb       Impact factor: 1.902

8.  Establishment and characterization of cell lines from liver fluke-associated cholangiocarcinoma induced in a hamster model.

Authors:  T Tengchaisri; N Prempracha; W Thamavit; S Boonpucknavig; S Sriurairatana; S Sirisinha
Journal:  Southeast Asian J Trop Med Public Health       Date:  1995-06       Impact factor: 0.267

9.  "Intestinal-type" of adenocarcinoma preferentially induced in right/caudate liver lobes of rats treated with furan.

Authors:  L W Elmore; A E Sirica
Journal:  Cancer Res       Date:  1993-01-15       Impact factor: 12.701

Review 10.  A review and update on cholangiocarcinoma.

Authors:  Matthew J Olnes; Rodrigo Erlich
Journal:  Oncology       Date:  2004       Impact factor: 2.935

View more
  7 in total

Review 1.  Xenotransplantation models to study the effects of toxicants on human fetal tissues.

Authors:  Daniel J Spade; Elizabeth V McDonnell; Nicholas E Heger; Jennifer A Sanders; Camelia M Saffarini; Philip A Gruppuso; Monique E De Paepe; Kim Boekelheide
Journal:  Birth Defects Res B Dev Reprod Toxicol       Date:  2014-12-04

2.  Insulin-Like Growth Factor-1 Receptor Targeted Fluorescent Imaging for Gallbladder Cancer in Orthotopic Mouse Models.

Authors:  Jung Ha Choi; Jeong Youp Park
Journal:  Gut Liver       Date:  2021-09-01       Impact factor: 4.321

3.  Tumor necrosis factor-α promotes the lymphangiogenesis of gallbladder carcinoma through nuclear factor-κB-mediated upregulation of vascular endothelial growth factor-C.

Authors:  Qiang Du; Lei Jiang; Xiaoqian Wang; Meiping Wang; Feifei She; Yanling Chen
Journal:  Cancer Sci       Date:  2014-10-09       Impact factor: 6.716

4.  Homoharringtonine, a clinically approved anti-leukemia drug, sensitizes tumor cells for TRAIL-induced necroptosis.

Authors:  Stephan Philipp; Justyna Sosna; Johannes Plenge; Holger Kalthoff; Dieter Adam
Journal:  Cell Commun Signal       Date:  2015-04-29       Impact factor: 5.712

5.  TRAIL-induced programmed necrosis as a novel approach to eliminate tumor cells.

Authors:  Susann Voigt; Stephan Philipp; Parvin Davarnia; Supandi Winoto-Morbach; Christian Röder; Christoph Arenz; Anna Trauzold; Dieter Kabelitz; Stefan Schütze; Holger Kalthoff; Dieter Adam
Journal:  BMC Cancer       Date:  2014-02-07       Impact factor: 4.430

6.  Precision modeling of gall bladder cancer patients in mice based on orthotopic implantation of organoid-derived tumor buds.

Authors:  Shingo Kato; Kentaro Fushimi; Yuichiro Yabuki; Yoshiaki Maru; Sho Hasegawa; Tetsuya Matsuura; Daisuke Kurotaki; Akihiro Suzuki; Noritoshi Kobayashi; Masato Yoneda; Takuma Higurashi; Makiko Enaka; Tomohiko Tamura; Yoshitaka Hippo; Atsushi Nakajima
Journal:  Oncogenesis       Date:  2021-04-17       Impact factor: 7.485

Review 7.  Recent Advances in Implantation-Based Genetic Modeling of Biliary Carcinogenesis in Mice.

Authors:  Masashi Izumiya; Shingo Kato; Yoshitaka Hippo
Journal:  Cancers (Basel)       Date:  2021-05-11       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.